Garippa becomes new SynCardia CEO, Ford exits for MicroMed

Justine Varieur Cadet | | Health Imaging | Artificial Intelligence
Rodger Ford, the SynCardia Systems’ CEO for the past six years, has stepped down. SynCardia President Michael Garippa has taken over as CEO in addition to his current role.

Ford is joining MicroMed Cardiovascular, manufacturer of the HeartAssist 5 left ventricular assist device, as CEO and chairman of the board.

Prior to joining SynCardia, Garippa served as the CEO and president of TandemHeart for eight years.  

Ford became a director of SynCardia in May 2004. SynCardia received FDA approval of the Total Artificial Heart in October of that year. In July 2005, Ford became the CEO and president, and joined the board of directors for MicroMed in July 2008.

Justine Varieur Cadet

Related Content

New cardiac prevention paradigm explored in TRANSFORM trial using AI and CCTA
PHOTO GALLERY: Medical imaging technology at RSNA 2024
Cardiology, radiology specialists debate CCTA’s rise as a go-to imaging modality for CAD
Can large language models break language barriers in radiology reports?
Most patients want to know if AI is involved in their care
New algorithm is twice as accurate at predicting stroke timing compared to the standard of care

Around the web

Radiology Business
The biggest challenges facing radiology business managers in 2025

RBMA President Peter Moffatt discusses some of the biggest obstacles facing the specialty in the new year. 

Cardiovascular Business
New cardiac prevention paradigm explored in TRANSFORM trial using AI and CCTA

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

Cardiovascular Business
Cardiology practices pay $17.7M to settle fraud allegations brought on by whistleblowers

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.